WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2023

Hedge fundSEC filingsCompare with another fundHoldings as of 2023-12-31, filed 2024-02-14

Avidity Partners Management LP disclosed 72 US equity positions worth $2.6bn in its Q4 2023 13F filing. Its largest position is ARVN at 4.7% of the reported book, followed by BSX and TMO. Versus Q3 2023 it opened 10 new positions, added to 24, reduced 31 and exited 21.

$2.6bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
72
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
4.7%
Largest position
The largest single position as a share of the reported equity book.
32.8%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
46
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2023: 10 new, 24 added, 31 reduced, 21 exited

50 of 72
ARVN ARVINAS INCHealthcare4.7%$123m2.99m+14%added
BSX BOSTON SCIENTIFIC CORPHealthcare4.2%$109m1.89m−8.5%reduced
TMO THERMO FISHER SCIENTIFIC INCHealthcare3.7%$96.9m182,600–new
ACHC ACADIA HEALTHCARE COMPANY INHealthcare3.4%$89.9m1.16m+62%added
NBIX NEUROCRINE BIOSCIENCES INCHealthcare3.3%$86.7m658,000+0.9%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare3.3%$85.4m3.95m+40%added
NTRA NATERA INCHealthcare2.7%$69.5m1.11m+23%added
DHR DANAHER CORP DELHealthcare2.6%$67.1m290,000+64%added
THC TENET HEALTHCARE CORPHealthcare2.5%$65.8m871,000−9.6%reduced
KRTX KARUNA THERAPEUTICS INC–2.5%$65.2m206,000−28%reduced
FUSION PHARMACEUTICALS INC no ticker–2.4%$62.5m6.50m+12%added
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.3%$60.2m489,119−39%reduced
REGN REGENERON PHARMACEUTICALSHealthcare2.3%$59.7m68,000+17%added
CVS CVS HEALTH CORPHealthcare2.2%$58.4m740,000–new
2655787D BLUEPRINT MEDICINES CORP–2.2%$56.7m615,000−18%reduced
IMGNEUR IMMUNOGEN INC–2.1%$54.2m1.83m−4.6%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare2.1%$54.1m1.52m−29%reduced
UTHR UNITED THERAPEUTICS CORP DELHealthcare2.0%$52.2m237,202–new
RCKT ROCKET PHARMACEUTICALS INCHealthcare2.0%$51.5m1.72m+8.3%added
ITCIEUR INTRA-CELLULAR THERAPIES INC–1.9%$50.9m710,000−11%reduced
LLY ELI LILLY & COHealthcare1.9%$49.5m85,000+13%added
BHVN BIOHAVEN LTDHealthcare1.9%$49.1m1.15m−11%reduced
AVTR AVANTOR INCHealthcare1.9%$48.4m2.12m–new
ZTS ZOETIS INCHealthcare1.8%$47.4m240,000−8.4%reduced
HUM HUMANA INCHealthcare1.8%$45.8m100,000−9.3%reduced
ABBV ABBVIE INCHealthcare1.7%$44.1m284,405–new
GPCR STRUCTURE THERAPEUTICS INCHealthcare1.7%$44.0m1.08m+116%added
ALGN ALIGN TECHNOLOGY INCHealthcare1.6%$42.7m155,800–new
LEGN LEGEND BIOTECH CORPHealthcare1.6%$41.2m685,000−29%reduced
BDX BECTON DICKINSON & COHealthcare1.5%$40.4m165,706−42%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.5%$40.4m844,500+55%added
MCK MCKESSON CORPHealthcare1.5%$39.6m85,500−49%reduced
XENE XENON PHARMACEUTICALS INCHealthcare1.4%$37.6m815,993+154%added
SGRY SURGERY PARTNERS INCHealthcare1.4%$37.3m1.17m−13%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare1.4%$36.6m459,400+55%added
CRBU CARIBOU BIOSCIENCES INCHealthcare1.4%$36.4m6.36m+5.1%added
PCVX VAXCYTE INCHealthcare1.4%$35.8m570,137−25%reduced
NMRA NEUMORA THERAPEUTICS INC.Healthcare1.3%$33.9m1.99m+11%added
MIRM MIRUM PHARMACEUTICALS INCHealthcare1.3%$33.7m1.14m0.0%held
UNH UNITEDHEALTH GROUP INCHealthcare1.2%$30.8m58,500−48%reduced
PRVA PRIVIA HEALTH GROUP INCHealthcare1.1%$29.6m1.29m−17%reduced
ISRG INTUITIVE SURGICAL INCHealthcare1.1%$28.7m85,000–new
LNTH LANTHEUS HLDGS INCHealthcare0.9%$23.6m380,000−32%reduced
ANTX AN2 THERAPEUTICS INCHealthcare0.9%$23.4m1.14m+4.6%added
ACIU AC IMMUNE SAHealthcare0.9%$22.3m4.47m+50%added
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare0.8%$21.8m714,000−33%reduced
IMCR IMMUNOCORE HLDGS PLCHealthcare0.8%$20.5m300,200−14%reduced
CRNXGBP CRINETICS PHARMACEUTICALS IN–0.7%$18.8m529,000−13%reduced
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.6%$15.7m1.72m+6.4%added
VRNA VERONA PHARMA PLC–0.6%$15.5m780,900−5.9%reduced

Exited since Q3 2023

21 rows
CI THE CIGNA GROUP2.4%$59.4m
SRPT SAREPTA THERAPEUTICS INC2.2%$54.5m
MLTX MOONLAKE IMMUNOTHERAPEUTICS1.8%$44.3m
ZNTL ZENTALIS PHARMACEUTICALS INC1.7%$42.1m
DXCM DEXCOM INC1.4%$35.2m
BIIB BIOGEN INC1.2%$29.7m
HCA HCA HEALTHCARE INC1.1%$28.2m
UHS UNIVERSAL HLTH SVCS INC0.9%$22.9m
CUREVAC N V no ticker0.9%$21.3m
PRTA PROTHENA CORP PLC0.7%$18.4m
ROIV ROIVANT SCIENCES LTD0.7%$17.6m
VTYXUSD VENTYX BIOSCIENCES INC0.5%$12.3m
SDGR SCHRODINGER INC0.5%$11.3m
RAYZEBIO INC no ticker0.4%$11.1m
PACB PACIFIC BIOSCIENCES CALIF IN0.3%$8.6m
NVLSEUR ALPINE IMMUNE SCIENCES INC0.3%$7.5m
2JQ GRITSTONE BIO INC0.2%$4.7m
ATEC ALPHATEC HLDGS INC0.2%$4.0m
NSTGEUR NANOSTRING TECHNOLOGIES INC0.2%$4.0m
VERVE THERAPEUTICS INC no ticker0.2%$3.8m
ALT ALTIMMUNE INC0.1%$3.0m

Sector mix

  • Healthcare86.1%
  • Unclassified13.9%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters